Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tacrolimus Hexal vs Prograf in De Novo Renal Transplant
NCT01649427Phase 4Completed
- Sponsor
- Novartis
- Start
- Oct 2012
- Primary completion
- Aug 2015
- Modality
- RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of tacrolimus in kidney transplant rejection (2 arms), sponsored by Novartis. Primary endpoints: Change in Nankivell Glomerular Filtration Rate at Month 6 and Dose-normalized Tacrolimus 12-h Area Under the Curve at Month 1. Started Oct 2012; status: completed.
02
Drugs
tacrolimus
03
Conditions
kidney transplant rejection
Beyond the preview
Go deeper on NCT01649427.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01649427.